A Phase I Study of Bi-weekly Combination Therapy with S-1 and Docetaxel for Advanced or Recurrent Gastric Cancer

Background: S-1 is a novel oral fluorouracil antitumor drug that contains a combination of 3 pharmacological agents: tegafur (FT), a 5-fluorouracil (5-FU) prodrug, 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits the activity of dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2006-03, Vol.26 (2B), p.1455-1462
Hauptverfasser:	RINO, Yasushi, TAKANASHI, Yoshinori, YUKAWA, Norio, SAEKI, Hiroyuki, WADA, Hiroo, KANARI, Masahiro, YAMADA, Roppei, SATOH, Tsutomu, YAMAMOTO, Naoto, IMADA, Toshio
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Drug Administration Schedule Drug Combinations Female Gastroenterology. Liver. Pancreas. Abdomen Humans Male Medical sciences Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neoplasm Staging Oxonic Acid - administration & dosage Oxonic Acid - adverse effects Pyridines - administration & dosage Pyridines - adverse effects Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Taxoids - administration & dosage Taxoids - adverse effects Tegafur - administration & dosage Tegafur - adverse effects Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!